Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended Remdesivir and Nirmatrelvir/Ritonavir for Persistent COVID-19 in Immunocompromised Patients
NCT06610643Not yet recruiting
- Sponsor
- National Taiwan University Hospital
- Start
- Sep 2024
- Primary completion
- Sep 2026
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Randomised, open-label trial of remdesivir, Nirmatrelvir and ritonavir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by National Taiwan University Hospital. Primary endpoint: Proportion of SARS-CoV-2 CT > 30 at Day 14. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
remdesivirNirmatrelvirritonavir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06610643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06610643.